A recent study carried out by UK’s Medicines and Healthcare products Regulatory Authority (MHRA) has revealed a huge variability in research methods associated with microbiome studies performed internationally. Therefore, making setting global standards for microbiome research methods a necessity that can’t be ignored.
The study performed involved 23 laboratories across 4 continents and 11 countries evaluated new World Health Organization (WHO) International Reference Reagents to test current methodologies for characterizing bacterial composition.
The study revealed striking inconsistencies in laboratory performance. Species identification accuracy ranged widely from 63% to 100% with some laboratories missing up to one-third of the bacteria actually present. False positive rates varied from 0% to 41%, indicating that some labs reported bacteria that were not in the sample. Estimates of sample diversity also differed significantly, with labs detecting anywhere from 12 to 185 bacterial species in the same specimen.
This demonstrates a critical lack of standardization in current microbiome analysis, leading to substantial variability and reliability concerns when identifying and quantifying complex bacterial communities.
What makes Microbiome research an extremely important thing is how it directly influences treatments for conditions like IBD, metabolic syndrome, irritable bowel syndrome and colorectal cancer. Yet conflicting study results continue to challenge confidence in this fast-growing field.
The key source of variation lies in the application of "high throughput sequencing" methods used to characterize gut samples. These inconsistencies arise from multiple factors, including the choice of DNA sequencing technology, the bioinformatics software and databases used for analysis (where even minor updates to reference databases significantly affected results), and differences in laboratory protocols and techniques.
The study sets new, evidence-based Minimum Quality Criteria for four key microbiome reporting measures, giving laboratories worldwide a dependable framework to validate and improve their analysis methods. With the introduction of WHO International DNA Gut Reference Reagents, labs can now benchmark their performance using real-world standards and optimize their testing accuracy.
For patients, this means more reliable gut health research, greater confidence in microbiome-based treatments, and more accurate test results. These new quality benchmarks also accelerate the development of therapies for gut-related diseases. Ultimately, when your gut health is analyzed, the information clinicians rely on will be more precise leading to better decisions, better care, and better outcomes.
The study was funded by the Department of Health and Social Care’s Policy Research Program through the MHRA Regulatory Science Research Unit, with additional support from an Innovate UK SBRI award. It underscores the UK government’s commitment to advancing regulatory science, driving healthcare innovation and maintaining high quality standards.
Learn more: GovMHRA-led study reveals major inconsistencies in global microbiome research
